Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized condition, often associated with obesity and type 2 diabetes. Understanding its pathogenesis, diagnosis, and treatment is crucial for managing this global health concern.
NAFLD is characterized by excessive hepatic fat accumulation not due to alcohol consumption. It is a multifactorial disease, with insulin resistance and metabolic syndrome playing pivotal roles. The 'two-hit' hypothesis suggests that the first 'hit' involves accumulation of triglycerides in the liver, followed by a second 'hit' of increased oxidative stress leading to inflammation and fibrosis.
NAFLD is often asymptomatic and discovered incidentally during imaging studies. Liver function tests may show elevated aminotransferases. Ultrasound, CT, and MRI can detect hepatic steatosis, but liver biopsy remains the gold standard for diagnosing NAFLD and differentiating it from non-alcoholic steatohepatitis (NASH).
Management of NAFLD primarily focuses on lifestyle modifications including weight loss and increased physical activity. Pharmacological interventions are considered for patients with NASH or fibrosis. These include vitamin E, pioglitazone, and more recently, drugs targeting specific pathways involved in NAFLD pathogenesis, such as obeticholic acid and elafibranor. Liver transplantation is considered for end-stage liver disease.
NAFLD is a complex disease with a multifaceted pathogenesis. Its diagnosis often requires a high degree of clinical suspicion and appropriate use of diagnostic modalities. Advanced treatment approaches are being developed, targeting the specific mechanisms involved in the disease process. As our understanding of NAFLD continues to evolve, so too will our approach to its management, promising better outcomes for patients afflicted with this condition.
1.
Does Maintenance Therapy Extend Life in mCRC?
2.
What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains
3.
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
4.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
5.
Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients
1.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
2.
Hypogammaglobulinemia: A Comprehensive Guide for Patients and Caregivers
3.
Personalized Survivorship Navigation in Precision Cancer Care
4.
Hematopoietic Stem Cell Exhaustion in Blood Disorders
5.
Hematopoietic Clonal Competition in Blood Disorders
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Advances in Modern Cancer Treatment
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Early Warning Signs of Cancer
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation